STOCK TITAN

Oncolytics Biotech, Inc. Common Shares - ONCY STOCK NEWS

Welcome to our dedicated page for Oncolytics Biotech Common Shares news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech Common Shares stock.

Oncolytics Biotech Inc. (symbol: ONCY) is a pioneering biotechnology company dedicated to the development of oncolytic viruses as innovative cancer therapeutics. Their flagship product, pelareorep, is a unique immunotherapeutic agent designed to harness the power of the human reovirus to enhance the body's immune response against cancer. Pelareorep has shown promising potential in making tumors more responsive to a variety of oncology treatments by promoting an inflamed tumor phenotype.

The company's robust clinical development pipeline includes multiple human trials targeting some of the most prevalent cancers, such as breast, gastrointestinal, and pancreatic cancers. Notably, Oncolytics is conducting a Phase III trial for head and neck cancers and has several ongoing trials in advanced stages, including the GOBLET study, which explores the efficacy of pelareorep in combination with different chemotherapy regimens.

In breast cancer, Oncolytics is advancing towards registration-enabling studies for HR+/HER2- metastatic breast cancer, supported by compelling data from the BRACELET-1 and IND-213 randomized studies. The company is also making significant strides in pancreatic cancer research, recently receiving a US$5 million grant from the Pancreatic Cancer Action Network (PanCAN) for a new Phase 1/2 cohort in the GOBLET study, assessing pelareorep in combination with modified FOLFIRINOX and atezolizumab (Tecentriq®).

Financially, Oncolytics is well-positioned with a strong balance sheet and ongoing support from strategic partnerships and grants. The company’s collaborations with leading research institutions and oncology networks enhance its clinical programs and accelerate the development of pelareorep as a versatile cancer therapy. Oncolytics continues to innovate and push the boundaries of cancer treatment, aiming to bring new hope to patients worldwide.

Rhea-AI Summary
Oncolytics Biotech® Inc. to participate in fireside chat at Cantor Global Healthcare Conference 2023 with CEO Dr. Matt Coffey. One-on-one investor meetings available. Webcast link provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.45%
Tags
none
-
Rhea-AI Summary
Oncolytics Biotech CEO to participate in fireside chat at H.C. Wainwright conference on Sep 12, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
conferences
-
Rhea-AI Summary
Oncolytics Biotech announces positive results from Phase 2 trial in breast cancer and inclusion in Precision Promise trial for pancreatic cancer. Financials show $24.4 million in cash and a successful $15 million public offering. Management to host conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
conferences earnings
-
Rhea-AI Summary
Oncolytics Biotech announced that pelareorep has been selected for inclusion in Precision Promise, an adaptive Phase 3 clinical trial for pancreatic cancer. The trial aims to evaluate the combination of pelareorep with a checkpoint inhibitor and chemotherapeutic agents. If successful, this study could support the approval of pelareorep as a treatment for first-line metastatic pancreatic cancer. The trial design is expected to reduce costs by 50% compared to traditional trials and accelerate the development process by up to two years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.67%
Tags
Rhea-AI Summary
Oncolytics Biotech announced positive results from a phase 2 trial in HR+/HER2- metastatic breast cancer. The combination of pelareorep-paclitaxel reduced the risk of disease progression by 71% compared to paclitaxel monotherapy. The confirmed overall response rate was 37.5% with pelareorep-paclitaxel, compared to 13.3% with paclitaxel monotherapy. The 12-month progression-free survival rate was 32.8% for pelareorep-paclitaxel, compared to 0% for paclitaxel monotherapy and pelareorep-paclitaxel-avelumab. The company's breast cancer program is now phase 3-ready. Data will be discussed in a key opinion leader webinar.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.65%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Oncolytics Biotech Common Shares (ONCY)?

The current stock price of Oncolytics Biotech Common Shares (ONCY) is $0.9541 as of November 22, 2024.

What is the market cap of Oncolytics Biotech Common Shares (ONCY)?

The market cap of Oncolytics Biotech Common Shares (ONCY) is approximately 72.5M.

What is Oncolytics Biotech Inc. known for?

Oncolytics Biotech Inc. is known for developing pelareorep, an innovative oncolytic virus used as a potential cancer therapeutic to enhance the immune system's response to tumors.

What cancers is Oncolytics currently targeting?

Oncolytics is targeting a variety of cancers including breast, gastrointestinal, pancreatic, and head and neck cancers through its clinical trials and research programs.

What is pelareorep?

Pelareorep is Oncolytics Biotech’s proprietary formulation of the human reovirus, designed to stimulate immune responses and make tumors more susceptible to a range of oncology treatments.

What are the recent achievements of Oncolytics Biotech?

Recent achievements include advancing to Phase III trials in head and neck cancers, receiving a US$5 million grant for pancreatic cancer research, and positive Phase 2 data in metastatic breast cancer.

How is Oncolytics Biotech funded?

Oncolytics Biotech is funded through a mix of strategic partnerships, grants, and a robust cash position to support its clinical development programs and operations.

What is the GOBLET study?

The GOBLET study is a Phase 1/2 clinical trial exploring the efficacy of pelareorep in combination with chemotherapy and checkpoint inhibitors in gastrointestinal cancers, particularly pancreatic cancer.

What are the potential benefits of pelareorep?

Pelareorep has demonstrated potential benefits such as enhancing the immune system's ability to fight cancer, increasing tumor susceptibility to treatments, and promoting an inflamed tumor phenotype.

What is the focus of Oncolytics' current clinical trials?

Oncolytics' clinical trials focus on leveraging pelareorep in combination with various chemotherapy regimens and immunotherapies to treat multiple cancer types effectively.

What partnerships does Oncolytics Biotech have?

Oncolytics partners with leading research institutions, oncology networks, and pharmaceutical companies to accelerate the development and commercialization of its therapies.

Where can I find more information about Oncolytics Biotech?

More information about Oncolytics Biotech can be found on their official website at www.oncolyticsbiotech.com or through their social media channels on LinkedIn and X (formerly Twitter).

Oncolytics Biotech, Inc. Common Shares

Nasdaq:ONCY

ONCY Rankings

ONCY Stock Data

72.47M
74.22M
3.82%
1.76%
3.66%
Biotechnology
Healthcare
Link
United States of America
Calgary